⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for stage iv mantle cell lymphoma

Every month we try and update this database with for stage iv mantle cell lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaNCT00019708
Extranodal Marg...
Nodal Marginal ...
Non-Hodgkin Lym...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
tanespimycin
19 Years - National Cancer Institute (NCI)
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell LymphomaNCT00070447
Lymphoma
rituximab
cyclophosphamid...
doxorubicin hyd...
prednisone
vincristine sul...
yttrium Y 90 ib...
18 Years - National Cancer Institute (NCI)
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell LymphomaNCT01527149
Stage I Mantle ...
Stage II Contig...
Stage II Non-Co...
Stage III Mantl...
Stage IV Mantle...
Autologous Hema...
Cyclophosphamid...
Cytarabine
Dexamethasone
Doxorubicin Hyd...
Laboratory Biom...
Methotrexate
Ofatumumab
Vincristine Sul...
18 Years - 70 YearsRoswell Park Cancer Institute
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative DiseaseNCT00176475
Leukemia
Lymphoma
Multiple Myelom...
rituximab
therapeutic all...
18 Years - Rutgers, The State University of New Jersey
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's LymphomaNCT00244946
Lymphoma
therapeutic aut...
carmustine
cytarabine
etoposide
melphalan
peripheral bloo...
15 Years - 70 YearsBarbara Ann Karmanos Cancer Institute
Memory-enriched CAR-T Cells Immunotherapy for B Cell LymphomaNCT02652910
Recurrent Adult...
Recurrent Folli...
Recurrent Mantl...
Stage III Adult...
Stage III Folli...
Stage III Mantl...
Stage IV Adult ...
Stage IV Follic...
Stage IV Mantle...
CD19.CAR-T cell...
18 Years - 70 YearsXinqiao Hospital of Chongqing
Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell LymphomaNCT00003280
Lymphoma
rituximab
18 Years - 120 YearsSwiss Group for Clinical Cancer Research
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's LymphomaNCT00017381
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Extranodal Marg...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Stage I Adult D...
Stage I Adult D...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Small L...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Waldenström Mac...
rituximab
cyclophosphamid...
filgrastim
yttrium Y 90 ib...
peripheral bloo...
18 Years - 70 YearsNational Cancer Institute (NCI)
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent LymphomaNCT00980395
Lymphoma
Mantle Cell Lym...
Indolent Lympho...
SLL
rituximab
bortezomib
cladribine
18 Years - University of Arizona
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's LymphomaNCT00101244
Adult Grade III...
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
ispinesib
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202NCT00896662
Lymphoma
Solid Tumor
immunologic tec...
laboratory biom...
pharmacological...
18 Years - Vanderbilt-Ingram Cancer Center
Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaNCT00516412
Lymphoma
everolimus
molecular respo...
18 Years - Swiss Group for Clinical Cancer Research
Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line ChemotherapyNCT00727207
Lymphoma
everolimus
40 Years - Technical University of Munich
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's LymphomaNCT00278161
Leukemia
Lymphoma
Pegfilgrastim
Rituximab
Cyclophosphamid...
18 Years - 70 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic MalignancyNCT00891137
Leukemia
Lymphoma
Multiple Myelom...
Plasma Cell Neo...
Myelodysplastic...
human myeloid p...
12 Years - 65 YearsCellerant Therapeutics
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell CancersNCT00003163
Lymphoma
Multiple Myelom...
filgrastim
sargramostim
cyclophosphamid...
melphalan
autologous bone...
peripheral bloo...
radiation thera...
18 Years - National Cancer Institute (NCI)
Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell LymphomaNCT00020943
Lymphoma
filgrastim
rituximab
carmustine
cyclophosphamid...
cytarabine
doxorubicin hyd...
etoposide
leucovorin calc...
methotrexate
prednisone
vincristine sul...
peripheral bloo...
18 Years - 69 YearsAlliance for Clinical Trials in Oncology
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionNCT00118170
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Mult...
Splenic Margina...
Stage II Multip...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Multi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
sorafenib tosyl...
pharmacological...
18 Years - National Cancer Institute (NCI)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's LymphomaNCT00026429
Leukemia
Lymphoma
denileukin dift...
18 Years - National Cancer Institute (NCI)
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's LymphomaNCT00082823
Cancer
ziv-aflibercept
18 Years - 120 YearsRegeneron Pharmaceuticals
Rituximab Plus Interleukin-2 in Treating Patients With LymphomaNCT00003356
Lymphoma
aldesleukin
rituximab
18 Years - 75 YearsUniversity of Rochester
Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)NCT00005626
Leukemia
Lymphoma
Irinotecan
18 Years - H. Lee Moffitt Cancer Center and Research Institute
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's LymphomaNCT00003397
Lymphoma
filgrastim
rituximab
sargramostim
carmustine
cisplatin
cyclophosphamid...
dexamethasone
etoposide
gemcitabine hyd...
melphalan
paclitaxel
bone marrow abl...
peripheral bloo...
18 Years - 75 YearsUniversity of Maryland, Baltimore
Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic CancersNCT00003572
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
peripheral bloo...
mycophenolate m...
tacrolimus
allogeneic bone...
radiation thera...
18 Years - 70 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid CancerNCT00248430
Graft Versus Ho...
Leukemia
Lymphoma
Multiple Myelom...
aldesleukin
therapeutic all...
melphalan
bone marrow abl...
peripheral bloo...
18 Years - 69 YearsFred Hutchinson Cancer Center
Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell LymphomaNCT00003541
Lymphoma
filgrastim
CHOP regimen
carboplatin
cyclophosphamid...
doxorubicin hyd...
etoposide
ifosfamide
prednisone
vincristine sul...
peripheral bloo...
radiation thera...
18 Years - Memorial Sloan Kettering Cancer Center
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionNCT00118170
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Mult...
Splenic Margina...
Stage II Multip...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Multi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
sorafenib tosyl...
pharmacological...
18 Years - National Cancer Institute (NCI)
Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell LymphomaNCT00740415
Lymphoma
rituximab
bortezomib
dexamethasone
Bendamustine
65 Years - 80 YearsFrench Innovative Leukemia Organisation
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic SyndromeNCT00002989
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
busulfan
cyclophosphamid...
idarubicin
melphalan
radiation thera...
16 Years - 60 YearsNational Cancer Institute (NCI)
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin LymphomaNCT01045928
Adult Non-Hodgk...
Adult Grade III...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage I Adult B...
Stage I Adult D...
Stage I Adult D...
Stage I Adult D...
Stage I Adult I...
Stage I Adult L...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Small L...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Waldenstrom Mac...
lenalidomide
rituximab
polymerase chai...
nucleic acid se...
polymorphism an...
flow cytometry
laboratory biom...
18 Years - Case Comprehensive Cancer Center
UCN-01 in Treating Patients With Advanced CancerNCT00003289
Leukemia
Lymphoma
Unspecified Adu...
7-hydroxystauro...
18 Years - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic CancerNCT00010192
B-cell Adult Ac...
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
rituximab
aldesleukin
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell LymphomaNCT02242097
Contiguous Stag...
Noncontiguous S...
Stage I Mantle ...
Stage III Mantl...
Stage IV Mantle...
ibrutinib
laboratory biom...
18 Years - Northwestern University
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic CancerNCT00296023
Chronic Myelopr...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
anti-thymocyte ...
filgrastim
therapeutic all...
busulfan
fludarabine pho...
methotrexate
tacrolimus
nonmyeloablativ...
peripheral bloo...
18 Years - 75 YearsUniversity of California, San Francisco
PS-341 in Treating Patients With Advanced CancerNCT00006362
Leukemia
Lymphoma
Multiple Myelom...
Precancerous Co...
Unspecified Adu...
bortezomib
18 Years - Mayo Clinic
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By ChemotherapyNCT00003341
Anemia
Leukemia
Lymphoma
Multiple Myelom...
epoetin alfa
quality-of-life...
18 Years - Memorial Sloan Kettering Cancer Center
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic CancerNCT00290641
Chronic Myelopr...
Leukemia
Lymphoma
Myelodysplastic...
filgrastim
graft-versus-tu...
cyclophosphamid...
cyclosporine
fludarabine pho...
mycophenolate m...
umbilical cord ...
radiation thera...
- 45 YearsMasonic Cancer Center, University of Minnesota
Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or LymphomaNCT00006252
Leukemia
Lymphoma
fludarabine pho...
Cyclophosphamid...
PBSC
G-CSF
Donor lymphocyt...
- 69 YearsAlliance for Clinical Trials in Oncology
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic CancerNCT00782379
Leukemia
Lymphoma
Myelodysplastic...
busulfan
cyclophosphamid...
fludarabine pho...
mycophenolate m...
tacrolimus
allogeneic hema...
peripheral bloo...
18 Years - 60 YearsNorthside Hospital, Inc.
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's LymphomaNCT00110006
Lymphoma
rituximab
cyclophosphamid...
doxorubicin hyd...
prednisone
vincristine sul...
positron emissi...
fludeoxyglucose...
18 Years - Case Comprehensive Cancer Center
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent LymphomaNCT00980395
Lymphoma
Mantle Cell Lym...
Indolent Lympho...
SLL
rituximab
bortezomib
cladribine
18 Years - University of Arizona
Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell LymphomaNCT00101101
Lymphoma
Cyclophosphamid...
Doxorubicin
Vincristine
Prednisone
Dexamethasone
Autologous Tumo...
IL-2
18 Years - H. Lee Moffitt Cancer Center and Research Institute
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell CancersNCT00003163
Lymphoma
Multiple Myelom...
filgrastim
sargramostim
cyclophosphamid...
melphalan
autologous bone...
peripheral bloo...
radiation thera...
18 Years - National Cancer Institute (NCI)
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell LymphomaNCT00376961
Lymphoma
rituximab
bortezomib
cyclophosphamid...
doxorubicin hyd...
prednisone
vincristine sul...
18 Years - 120 YearsSWOG Cancer Research Network
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous LeukemiaNCT00275080
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Blastic Phase C...
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Secondary Acute...
Splenic Margina...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Untreated Adult...
Untreated Adult...
vorinostat
decitabine
18 Years - National Cancer Institute (NCI)
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell LymphomaNCT02242097
Contiguous Stag...
Noncontiguous S...
Stage I Mantle ...
Stage III Mantl...
Stage IV Mantle...
ibrutinib
laboratory biom...
18 Years - Northwestern University
Tipifarnib in Treating Patients With Advanced Hematologic CancerNCT00005967
Chronic Myelopr...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
tipifarnib
18 Years - National Cancer Institute (NCI)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's LymphomaNCT00026429
Leukemia
Lymphoma
denileukin dift...
18 Years - National Cancer Institute (NCI)
Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's LymphomaNCT00387959
Leukemia
Lymphoma
filgrastim
rituximab
cyclophosphamid...
cyclosporine
fludarabine pho...
mycophenolate m...
allogeneic hema...
umbilical cord ...
total-body irra...
18 Years - 70 YearsMemorial Sloan Kettering Cancer Center
UCN-01 in Treating Patients With Advanced CancerNCT00003289
Leukemia
Lymphoma
Unspecified Adu...
7-hydroxystauro...
18 Years - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or LeukemiaNCT00004084
Leukemia
Lymphoma
indium In 111 L...
yttrium Y 90 ep...
18 Years - Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell LymphomaNCT01527149
Stage I Mantle ...
Stage II Contig...
Stage II Non-Co...
Stage III Mantl...
Stage IV Mantle...
Autologous Hema...
Cyclophosphamid...
Cytarabine
Dexamethasone
Doxorubicin Hyd...
Laboratory Biom...
Methotrexate
Ofatumumab
Vincristine Sul...
18 Years - 70 YearsRoswell Park Cancer Institute
Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell LymphomaNCT00003280
Lymphoma
rituximab
18 Years - 120 YearsSwiss Group for Clinical Cancer Research
Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's LymphomaNCT00018954
Leukemia
Lymphoma
asparaginase
cyclophosphamid...
cytarabine
daunorubicin hy...
doxorubicin hyd...
etoposide
ifosfamide
mercaptopurine
methotrexate
prednisone
vincristine sul...
conventional su...
radiation thera...
- National Institutes of Health Clinical Center (CC)
Bortezomib in Treating Patients With Mantle Cell LymphomaNCT00030875
Lymphoma
bortezomib
18 Years - 120 YearsCanadian Cancer Trials Group
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic CancerNCT00004061
Leukemia
Lymphoma
Oral Complicati...
filgrastim
palifermin
cyclophosphamid...
etoposide
ifosfamide
peripheral bloo...
quality-of-life...
radiation thera...
18 Years - 65 YearsNational Cancer Institute (NCI)
Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell LymphomaNCT00020943
Lymphoma
filgrastim
rituximab
carmustine
cyclophosphamid...
cytarabine
doxorubicin hyd...
etoposide
leucovorin calc...
methotrexate
prednisone
vincristine sul...
peripheral bloo...
18 Years - 69 YearsAlliance for Clinical Trials in Oncology
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell LymphomaNCT00006747
Graft Versus Ho...
Lymphoma
carmustine
melphalan
etoposide
cytarabine
tacrolimus
methotrexate
sargramostim
transplant
- 59 YearsAlliance for Clinical Trials in Oncology
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous TherapyNCT00006220
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
arsenic trioxid...
tretinoin
15 Years - Washington University School of Medicine
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic CancerNCT00004061
Leukemia
Lymphoma
Oral Complicati...
filgrastim
palifermin
cyclophosphamid...
etoposide
ifosfamide
peripheral bloo...
quality-of-life...
radiation thera...
18 Years - 65 YearsNational Cancer Institute (NCI)
VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's LymphomaNCT00036946
Lymphoma
Unspecified Adu...
ziv-aflibercept
25 Years - 120 YearsRegeneron Pharmaceuticals
Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's LymphomaNCT00053027
Lymphoma
rituximab
cladribine
18 Years - Alliance for Clinical Trials in Oncology
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's LymphomaNCT00045266
Lymphoma
Unspecified Adu...
ziv-aflibercept
25 Years - 120 YearsRegeneron Pharmaceuticals
Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell LymphomaNCT00053092
Lymphoma
rituximab
cyclophosphamid...
fludarabine pho...
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's LymphomaNCT00244946
Lymphoma
therapeutic aut...
carmustine
cytarabine
etoposide
melphalan
peripheral bloo...
15 Years - 70 YearsBarbara Ann Karmanos Cancer Institute
Donor Stem Cell Transplant in Treating Patients With Mantle Cell LymphomaNCT00720447
Lymphoma
alemtuzumab
donor lymphocyt...
carmustine
cytarabine
etoposide
melphalan
allogeneic bone...
peripheral bloo...
18 Years - National Cancer Institute (NCI)
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's LymphomaNCT00083213
Cancer
ziv-aflibercept
18 Years - 120 YearsRegeneron Pharmaceuticals
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantNCT00725062
Graft Versus Ho...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
CD4+CD25+ regul...
allogeneic hema...
18 Years - 70 YearsMasonic Cancer Center, University of Minnesota
Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell LymphomaNCT00003311
Lymphoma
filgrastim
cyclophosphamid...
cytarabine
dexamethasone
doxorubicin hyd...
methotrexate
vincristine sul...
16 Years - M.D. Anderson Cancer Center
Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell LymphomaNCT00004231
Lymphoma
aldesleukin
filgrastim
recombinant int...
busulfan
cyclophosphamid...
cytarabine
doxorubicin hyd...
leucovorin calc...
methotrexate
prednisone
teniposide
vincristine sul...
allogeneic bone...
autologous bone...
peripheral bloo...
18 Years - Northwestern University
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's LymphomaNCT00003338
Lymphoma
immunoscintigra...
technetium Tc 9...
16 Years - 120 YearsGilead Sciences
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's LymphomaNCT00244946
Lymphoma
therapeutic aut...
carmustine
cytarabine
etoposide
melphalan
peripheral bloo...
15 Years - 70 YearsBarbara Ann Karmanos Cancer Institute
Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell LymphomaNCT00101101
Lymphoma
Cyclophosphamid...
Doxorubicin
Vincristine
Prednisone
Dexamethasone
Autologous Tumo...
IL-2
18 Years - H. Lee Moffitt Cancer Center and Research Institute
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's LymphomaNCT00017381
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Extranodal Marg...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Stage I Adult D...
Stage I Adult D...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Small L...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Waldenström Mac...
rituximab
cyclophosphamid...
filgrastim
yttrium Y 90 ib...
peripheral bloo...
18 Years - 70 YearsNational Cancer Institute (NCI)
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell TransplantNCT02797470
HIV Infection
Mature T-Cell a...
Plasmablastic L...
Recurrent Adult...
Recurrent Adult...
Recurrent Burki...
Recurrent Folli...
Stage III Folli...
Stage III Mantl...
Stage IV Follic...
Stage IV Mantle...
Autologous Hema...
Carmustine
Cytarabine
Etoposide
Laboratory Biom...
Lentivirus Vect...
Melphalan
Peripheral Bloo...
18 Years - AIDS Malignancy Consortium
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast CancerNCT00005993
Breast Cancer
Lymphoma
aldesleukin
filgrastim
recombinant hum...
peripheral bloo...
18 Years - 65 YearsMasonic Cancer Center, University of Minnesota
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantNCT00725062
Graft Versus Ho...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
CD4+CD25+ regul...
allogeneic hema...
18 Years - 70 YearsMasonic Cancer Center, University of Minnesota
Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's LymphomaNCT00028665
Lymphoma
filgrastim
rituximab
carmustine
cisplatin
cyclophosphamid...
etoposide
bone marrow abl...
peripheral bloo...
radiation thera...
12 Years - 65 YearsCase Comprehensive Cancer Center
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell LymphomaNCT01412879
Lymphoma
rituximab
bendamustine hy...
cyclophosphamid...
cytarabine
dexamethasone
doxorubicin hyd...
leucovorin calc...
methotrexate
vincristine sul...
18 Years - 65 YearsSWOG Cancer Research Network
Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's LymphomaNCT00443976
Non-Hodgkins Ly...
Unspecified Adu...
Aurora kinase i...
18 Years - Canadian Cancer Trials Group
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: